180 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
and disposing of the Common Stock.
This discussion is for informational purposes only and is not tax advice. You should consult your own independent tax … independent tax advisors with respect to applicable tax rates and netting rules for capital gains and losses. Certain limitations exist on the deduction
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
and in the other documents incorporated by reference into this prospectus supplement from our own internal estimates and research, as well as from independent … prospectus. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties
8-K
EX-4.2
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest … price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent
8-K
EX-4.1
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest … price per share of Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent
8-K
EX-4.3
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith … Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding
424B3
wldt1hdw5
2 Feb 24
Prospectus supplement
12:00am
DEF 14C
zvcm leglybcxcj1qp6u
29 Jan 24
Information statement
8:00am
PRE 14C
ocj pjqk444v4xn
17 Jan 24
Preliminary information
5:05pm
8-K
EX-4.1
s2l7fcf1fflqdp7 yx
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.2
jtc0 isde658g
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.2
1k11j3grez
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm